Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.57 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.57 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.57 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.57 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.57 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.57 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.57 |
| ▸ | ACHE | P22303 | 4/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7259722 | 1.00 | TDP1 (0.64) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL24468061 | 1.00 | TDP1 (0.64) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL6575878 | 0.98 | TDP1 (0.61) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL766369 | 0.94 | TDP1 (0.59) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL8862878 | 0.90 | TDP1 (0.75) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL2604742 | 0.90 | TDP1 (0.75) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL6777483 | 0.90 | TDP1 (0.75) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL8862728 | 0.90 | TDP1 (0.75) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL8863154 | 0.90 | TDP1 (0.75) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL8863094 | 0.90 | TDP1 (0.75) | TDP1L3MBTL1CHRM2MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4700124-A2 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | Alnylam Pharmaceuticals, Inc. (US) | 2026-02-25 | — | — | EP | disclosed |
| US-12398121-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2025-08-26 | — | — | US | disclosed |
| US-20250075208-A1 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | BANK OF AMERICA, N.A. | 2025-03-06 | — | — | US | disclosed |
| US-12173288-B2 | Oligonucleotide-ligand conjugates and process for their preparation | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-12-24 | — | — | US | disclosed |
| WO-2023113456-A1 | NOVEL COMPOUND FOR DEGRADING TARGET PROTEIN OR POLYPEPTIDE BY USING POLYUBIQUITINATION | (주)프레이저테라퓨틱스 | 2023-06-22 | — | — | WO | disclosed |
| WO-2023113456-A1 | NOVEL COMPOUND FOR DEGRADING TARGET PROTEIN OR POLYPEPTIDE BY USING POLYUBIQUITINATION | (주)프레이저테라퓨틱스 | 2023-06-22 | — | — | WO | disclosed |
| US-20230122310-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2023-04-20 | — | — | US | disclosed |
| US-20230122310-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2023-04-20 | — | — | US | disclosed |
| US-20220348914-A1 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | BANK OF AMERICA, N.A. | 2022-11-03 | — | — | US | disclosed |
| EP-4039278-A1 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | Alnylam Pharmaceuticals, Inc. (US) | 2022-08-10 | — | — | EP | disclosed |
| US-20120053336-A1 | Nucleic Acid Labelling Compounds | AFFYMETRIX, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| US-8076072-B2 | Nucleic acid labeling compounds | AFFYMETRIX, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-8026057-B2 | Nucleic acid labeling compounds | AFFYMETRIX, INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-20110082289-A1 | Nucleic Acid Labeling Compounds | AFFYMETRIC, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-7468243-B2 | Nucleotide sequence labelling compoumd four use as tool in genetic engineering | AFFYMETRIX, INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-20080287667-A1 | Nucleic Acid Labeling Compounds | AFFYMETRIX, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| EP-1385829-A4 | NUCLEIC ACID LABELING COMPOUNDS | AFFYMETRIX INC (US) | 2005-10-19 | — | — | EP | disclosed |
| EP-1385829-A2 | NUCLEIC ACID LABELING COMPOUNDS | Affymetrix, Inc. (US) | 2004-02-04 | — | — | EP | disclosed |
| US-20020182625-A1 | Nucleotide sequence labelling compoumd four use as tool in genetic engineering | AFFYMETRIX, INC. | 2002-12-05 | — | — | US | disclosed |
| WO-2002072779-A2 | NUCLEIC ACID LABELING COMPOUNDS | AFFYMETRIX, INC. (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12398121-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NCOA1, NCOR1, NCOA3 | TDP1 3764/4885L3MBTL1 3229/4885CHRM2 4655/4885 |
| US-20110082289-A1 | Nucleic Acid Labeling Compounds | RNGTT, DUT, FBL | TDP1 207/4885L3MBTL1 1158/4885CHRM2 4885/4885 |
| US-20080287667-A1 | Nucleic Acid Labeling Compounds | RNGTT, DUT, FBL | TDP1 275/4885L3MBTL1 1152/4885CHRM2 4885/4885 |
| US-20220348914-A1 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | IGF2R, IRS1, INSR | TDP1 1363/4885L3MBTL1 1657/4885CHRM2 3553/4885 |
| US-12173288-B2 | Oligonucleotide-ligand conjugates and process for their preparation | IGF2R, IRS1, INSR | TDP1 1363/4885L3MBTL1 1657/4885CHRM2 3553/4885 |
| US-20120053336-A1 | Nucleic Acid Labelling Compounds | RNGTT, DUT, FBL | TDP1 215/4885L3MBTL1 1039/4885CHRM2 4885/4885 |
| US-20230122310-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NCOA1, NCOR1, NCOA3 | TDP1 3764/4885L3MBTL1 3229/4885CHRM2 4655/4885 |
| US-20250075208-A1 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | IGF2R, IRS1, INSR | TDP1 1363/4885L3MBTL1 1657/4885CHRM2 3553/4885 |
| US-20020182625-A1 | Nucleotide sequence labelling compoumd four use as tool in genetic engineering | RNGTT, POLM, RNMT | TDP1 239/4885L3MBTL1 470/4885CHRM2 4855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.